Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Use of continuous glucose monitoring (CGM) systems is being rapidly adopted as standard of care for insulin-requiring patients with diabetes. The PROMISE study (NCT03808376) evaluated the accuracy and safety of the next-generation implantable Eversense CGM system for up to 180 days. Methods: This was a prospective multicenter study involving 181 subjects with diabetes at 8 USA sites. All subjects were inserted with a primary sensor. Ninety-six subjects had a second sensor, either an identical sensor or a modified sensor (sacrificial boronic acid [SBA]), inserted in their other arm (53 and 43 subjects, respectively). Accuracy was evaluated by comparing CGM to YSI 2300 glucose analyzer (Yellow Springs Instrument [YSI]) values during 10 clinic visits (day 1–180). Confirmed event detection rates, calibration stability, sensor survival, and serious adverse events (SAEs) were evaluated. Results: For primary sensors, the percent CGM readings within 20%/20% of YSI values was 92.9%; overall mean absolute relative difference (MARD) was 9.1%. The confirmed alert detection rate at 70 mg/dL was 93% and at 180 mg/dL was 99%. The median percentage of time for one calibration per day was 56%. Sixty-five percent of the primary sensors survived to 180 days. For the SBA sensors, the percent CGM readings within 20%/20% of YSI values was 93.9%; overall MARD was 8.5%. The confirmed alert detection rate at 70 mg/dL was 94% and at 180 mg/dL was 99%. The median percentage of time for one calibration per day was 63%. Ninety percent of the SBA sensors survived to 180 days. No device- or insertion/removal procedure-related SAEs were reported. Conclusion: These data show the next-generation Eversense CGM system had sustained accuracy and safety up to 180 days, with an improved calibration scheme and survival, using the primary or SBA sensors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“In addition, analysis of real-time CGM data allows patients and their health care providers to analyze patterns and trends to alter aspects of the diabetes regimen, as well as determine if established targets for glucose levels, such as time in range and percentage of time spent above and time spent below range, are b…”
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“Importantly, both wear times exceed the recommended time of 70% for diabetes management and data analysis(2) and the suggested time of 80% as a criterion to enter clinical trials, which assess CGM effectiveness.(4,11,12)”
BackgroundLind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes
Slattery, D., & Choudhary, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0051 · Cited by 87 · cited 1×
“Importantly, both wear times exceed the recommended time of 70% for diabetes management and data analysis(2) and the suggested time of 80% as a criterion to enter clinical trials, which assess CGM effectiveness.(4,11,12)”
BackgroundLorenz, C., Sandoval, W., & Mortellaro, M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0028 · Cited by 80 · cited 1×
“The interferants of the original sensor were previously shown to be (1) intravenously administered mannitol or sorbitol or those components administered as an irrigation solution of peritoneal dialysis solution and (2) the tetracycline class of antibiotics.(13) Substances may interfere with the Eversense sensor by cau…”
MethodDeiss, D., Irace, C., Carlson, G., Tweden, K. S., & Kaufman, F. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0159 · Cited by 44
Self-citationReal-World Data from the First U.S. Commercial Users of an Implantable Continuous Glucose Sensor
Sanchez, P., Ghosh-Dastidar, S., Tweden, K. S., & Kaufman, F. R. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0234 · Cited by 40
Self-citation
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Self-citationWearable Electrochemical Glucose Sensors in Diabetes Management: A Comprehensive Review
Saha, T., Del Caño, R., Mahato, K., De la Paz, E., Chen, C., Ding, S., Yin, L., & Wang, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00078 · Cited by 442
Opportunities and challenges in the diagnostic utility of dermal interstitial fluid
Friedel, M., Thompson, I. A. P., Kasting, G., Polsky, R., Cunningham, D., Soh, H. T., & Heikenfeld, J. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00998-9 · Cited by 360
7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Metadata
- Authors
- Garg, S. K., Liljenquist, D., Bode, B., Christiansen, M. P., Bailey, T. S., Brazg, R. L., Denham, D. S., Chang, A. R., Akturk, H. K., Dehennis, A., Tweden, K. S., & Kaufman, F. R.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2022-02-01
- Volume
- 24
- Issue
- 2
- Pages
- 84-92
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W3200310242
- Cited by
- 83
- References
- 9
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. https://app.cochat.ai/papers/10.1089/dia.2021.0182
- The paper
- Garg, S. K., Liljenquist, D., Bode, B., Christiansen, M. P., Bailey, T. S., Brazg, R. L., Denham, D. S., Chang, A. R., Akturk, H. K., Dehennis, A., Tweden, K. S., & Kaufman, F. R. (2022). Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2021.0182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.